Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations

Movement Disorders : Official Journal of the Movement Disorder Society
Philippe HuotSusan H Fox

Abstract

Well-formed visual hallucinations (VH) are common in patients with Parkinson's disease (PD). The pathophysiology of VH in PD is unknown but may involve structures mediating visual processing such as the inferior temporal cortex. Serotonergic type 2A (5-HT(2A)) receptors have been linked to many psychiatric disorders, including psychosis. We hypothesized that enhanced 5-HT(2A) receptor levels may be involved in VH in PD. Autoradiographic binding using [(3)H]-ketanserin and spiperone, to define 5-HT(2A) receptors, was performed in 6 PD patients with VH, 6 PD patients without VH, and 5 healthy, age-matched controls. The cerebral regions studied included the orbitofrontal cortex, inferolateral temporal cortex, motor cortex, striatum, and substantia nigra. There was a significant (45.6%) increase in the levels of [(3)H]-ketanserin binding in the inferolateral temporal cortex of PD patients with VH when compared with PD patients without VH (54.3 +/- 5.2 fmol/mg vs. 37.3 +/- 4.3 fmol/mg, P = 0.039). Additionally, there was a significant increase in the levels of 5-HT(2A) receptors in the motor cortex of all PD patients taken as a group when compared with controls (57.8 +/- 5.7 fmol/mg vs. 41.2 +/- 2.6 fmol/mg, P = 0.0297). These resul...Continue Reading

References

May 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·R M WoodwardR Miledi
Jan 1, 1992·Trends in Neurosciences·M A Goodale, A D Milner
Nov 1, 1991·Journal of Neuropathology and Experimental Neurology·W Paulus, K Jellinger
Aug 1, 1987·Annals of Neurology·R J D'AmatoS H Snyder
May 1, 1967·Neurology·M M Hoehn, M D Yahr
Jan 1, 1995·Brain Research. Brain Research Reviews·A Parent, L N Hazrati
Jan 1, 1995·Journal of Neuropathology and Experimental Neurology·J P VonsattelE P Richardson
Aug 6, 1996·Proceedings of the National Academy of Sciences of the United States of America·F A Middleton, P L Strick
Jan 9, 1999·Human Brain Mapping·E HalgrenB R Rosen
Mar 11, 1999·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
Mar 29, 2000·Brain : a Journal of Neurology·G FénelonM Ziégler
Dec 5, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·S H Fox, J M Brotchie
Aug 3, 2001·Nature Reviews. Neuroscience·E BezardC E Gross
Feb 15, 2002·Brain : a Journal of Neurology·A J HardingG M Halliday
Oct 31, 2002·Human Psychopharmacology·Marie NaughtonBrian E. Leonard
Mar 27, 2004·The Journal of Pharmacology and Experimental Therapeutics·Christopher BishopPaul D Walker
Oct 12, 2004·Nature Neuroscience·Michael S BeauchampAlex Martin
Oct 16, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Nico J DiederichGlenn T Stebbins
Sep 6, 2005·Biological Psychiatry·Maria A OquendoVictoria Arango
Jul 29, 2006·Science·Noelia V WeisstaubJay A Gingrich
Aug 8, 2006·Nature Neuroscience·Kalanit Grill-SpectorDavid Ress
Sep 29, 2006·Proceedings of the National Academy of Sciences of the United States of America·Samarjit BhattacharyyaMitradas M Panicker
Apr 13, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Giovanni FabbriniChristopher G Goetz
Apr 25, 2007·Brain : a Journal of Neurology·Manolo CartaAnders Björklund
Sep 6, 2008·Progress in Brain Research·Manolo CartaAnders Björklund
Sep 30, 2008·Journal of Neurology·Naroa Ibarretxe-BilbaoCarme Junqué

❮ Previous
Next ❯

Citations

Jul 3, 2013·Experimental Brain Research·Philippe Huot, Susan H Fox
Nov 28, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Carolina MuguruzaJavier González-Maeso
Jan 28, 2014·Current Treatment Options in Neurology·Jennifer G Goldman, Samantha Holden
Feb 1, 2014·Brain : a Journal of Neurology·Jennifer G GoldmanChristopher G Goetz
Jul 6, 2014·BioMed Research International·Benjamin RollandRégis Bordet
Jan 31, 2013·Experimental Neurology·Nicolas MorinThérèse Di Paolo
Feb 16, 2013·Expert Opinion on Investigational Drugs·Tiago A MestreSusan H Fox
Feb 5, 2016·Pharmacological Reviews·David E Nichols
Jun 29, 2015·Brain : a Journal of Neurology·Maude Beaudoin-GobertVéronique Sgambato-Faure
Jun 4, 2011·Expert Opinion on Pharmacotherapy·Jennifer G GoldmanChristopher G Goetz
Aug 15, 2013·The International Journal of Neuropsychopharmacology·Adam L Halberstadt, Mark A Geyer
Feb 26, 2016·Expert Review of Neurotherapeutics·Stefan Hermanowicz, Neal Hermanowicz
May 2, 2017·ACS Chemical Neuroscience·Philippe HuotAndrew C McCreary
Aug 19, 2017·Expert Review of Clinical Pharmacology·Yasaman Kianirad, Tanya Simuni
Oct 20, 2017·Expert Opinion on Drug Discovery·Zeyad T Sahli, Frank I Tarazi
Mar 5, 2018·Journal of Neural Transmission·Véronique Sgambato, Léon Tremblay
Dec 11, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Isabelle Beaulieu-Boire, Anthony E Lang
Nov 20, 2018·Neurodegenerative Disease Management·Philippe Huot
Aug 11, 2016·Movement Disorders Clinical Practice·Daniel Weintraub
Jan 28, 2018·Current Psychiatry Reports·Shyam C Panchal, William G Ondo
Jan 24, 2019·Current Treatment Options in Neurology·Kasia Gustaw Rothenberg, Ryan Rajaram
Sep 15, 2018·Behavioural Pharmacology·Adjia HamadjidaPhilippe Huot
Jun 5, 2019·Expert Review of Clinical Pharmacology·Kelly E LyonsStuart Isaacson
Apr 24, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Glenda M HallidayCharles H Adler
Dec 1, 2017·Neurology. Clinical Practice·Trevor Hawkins, Brian D Berman
Mar 28, 2020·Journal of Neurology, Neurosurgery, and Psychiatry·John O'BrienDominic Ffytche
Jun 1, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Daniel Weintraub, David J Burn
Mar 16, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·Philippe HuotSusan H Fox
Dec 7, 2019·Journal of Geriatric Psychiatry and Neurology·Akira KuritaMegumi Suzuki
Jun 10, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Daniel Weintraub
Sep 29, 2017·Frontiers in Cellular Neuroscience·Cristina MiguelezPhilippe De Deurwaerdère
Oct 11, 2014·Expert Review of Clinical Pharmacology·Martin BroadstockAnne Corbett
Jun 22, 2017·Journal of Managed Care & Specialty Pharmacy·Neal HermanowiczCarolyn Farnum
Jun 30, 2018·The Mental Health Clinician·Jack J Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Related Papers

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Herbert Y MeltzerJoseph H Friedman
Progress in Neurobiology
Philippe HuotJonathan M Brotchie
Movement Disorders : Official Journal of the Movement Disorder Society
Naomi P VisanjiSusan H Fox
© 2021 Meta ULC. All rights reserved